Meeder Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Meeder Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12	Closed	-$5K	–	2475
2021 Q2	$5K	Buy	+12	New	+$4.28K	﹤0.01%	1929
2020 Q4	–	Sell	-67	Closed	-$23K	–	1876
2020 Q3	$23K	Buy	+67	New	+$22.8K	﹤0.01%	1123
2019 Q3	–	Sell	-18	Closed	-$9K	–	2135
2019 Q2	$9K	Buy	+18	New	+$12.7K	﹤0.01%	1476
2019 Q1	–	Sell	-147	Closed	-$128K	–	1696
2018 Q4	$128K	Buy	+147	New	+$137K	0.01%	584
2018 Q3	–	Sell	-59	Closed	-$54.5K	–	1534
2018 Q2	$54.5K	Buy	59 +35	+146%	+$37.6K	﹤0.01%	742
2018 Q1	$23K	Buy	+24	New	+$21.9K	﹤0.01%	857
2017 Q3	–	Sell	-9	Closed	-$3K	–	1625
2017 Q2	$3K	Sell	9 -11	-55%	-$4.24K	﹤0.01%	1310
2017 Q1	$10K	Buy	20 +2	+11%	+$828	﹤0.01%	852
2016 Q4	$6K	Buy	+18	New	+$7.62K	﹤0.01%	831

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Meeder Asset Management's ATRA Position: Q3 2021 in Review

Meeder Asset Management sold out of Atara Biotherapeutics (ATRA) in Q3 2021, closing a stake of 12 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in ATRA in Q4 2016 and held it in 9 quarters. The position peaked at $128K in Q4 2018. 140 funds tracked by Wall St. Rank hold ATRA as of Q3 2021.

Meeder Asset Management reported no remaining Atara Biotherapeutics position as of Q3 2021 after selling out during the quarter.
Meeder Asset Management sold 12 Atara Biotherapeutics shares in Q3 2021, an estimated $5K.
Meeder Asset Management first reported a position in Atara Biotherapeutics in Q4 2016 and held it in 9 quarters.
Meeder Asset Management's Atara Biotherapeutics position peaked at $128K in Q4 2018.
140 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2021.

Based on Meeder Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.